Literature DB >> 17447753

Analysis of HIV wild-type and mutant structures via in silico docking against diverse ligand libraries.

Max W Chang1, William Lindstrom, Arthur J Olson, Richard K Belew.   

Abstract

The FightAIDS@Home distributed computing project uses AutoDock for an initial virtual screen of HIV protease structures against a broad range of 1771 ligands including both known protease inhibitors and a diverse library of other ligands. The volume of results allows novel large-scale analyses of binding energy "profiles" for HIV structures. Beyond identifying potential lead compounds, these characterizations provide methods for choosing representative wild-type and mutant protein structures from the larger set. From the binding energy profiles of the PDB structures, a principal component analysis based analysis identifies seven "spanning" proteases. A complementary analysis finds that the wild-type protease structure 2BPZ best captures the central tendency of the protease set. Using a comparison of known protease inhibitors against the diverse ligand set yields an AutoDock binding energy "significance" threshold of -7.0 kcal/mol between significant, strongly binding ligands and other weak/nonspecific binding energies. This threshold captures nearly 98% of known inhibitor interactions while rejecting more than 95% of suspected noninhibitor interactions. These methods should be of general use in virtual screening projects and will be used to improve further FightAIDS@Home experiments.

Mesh:

Substances:

Year:  2007        PMID: 17447753     DOI: 10.1021/ci700044s

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  22 in total

1.  AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading.

Authors:  Oleg Trott; Arthur J Olson
Journal:  J Comput Chem       Date:  2010-01-30       Impact factor: 3.376

2.  Science wikinomics. Mass networking through the web creates new forms of scientific collaboration.

Authors:  Andrea Rinaldi
Journal:  EMBO Rep       Date:  2009-05       Impact factor: 8.807

3.  In-silico design and molecular docking evaluation of peptides derivatives from bacteriocins and porcine beta defensin-2 as inhibitors of Hepatitis E virus capsid protein.

Authors:  Carolina Quintero-Gil; Jaime Parra-Suescún; Albeiro Lopez-Herrera; Sergio Orduz
Journal:  Virusdisease       Date:  2017-06-09

4.  Virtual Screening with AutoDock: Theory and Practice.

Authors:  Sandro Cosconati; Stefano Forli; Alex L Perryman; Rodney Harris; David S Goodsell; Arthur J Olson
Journal:  Expert Opin Drug Discov       Date:  2010-06-01       Impact factor: 6.098

5.  Fragment-Based Analysis of Ligand Dockings Improves Classification of Actives.

Authors:  Richard K Belew; Stefano Forli; David S Goodsell; T J O'Donnell; Arthur J Olson
Journal:  J Chem Inf Model       Date:  2016-07-25       Impact factor: 4.956

6.  Virtual screening for HIV protease inhibitors: a comparison of AutoDock 4 and Vina.

Authors:  Max W Chang; Christian Ayeni; Sebastian Breuer; Bruce E Torbett
Journal:  PLoS One       Date:  2010-08-04       Impact factor: 3.240

7.  Structure-based and ligand-based virtual screening of novel methyltransferase inhibitors of the dengue virus.

Authors:  See Ven Lim; Mohd Basyaruddin A Rahman; Bimo A Tejo
Journal:  BMC Bioinformatics       Date:  2011-11-30       Impact factor: 3.169

8.  A virtual screening study of the acetylcholine binding protein using a relaxed-complex approach.

Authors:  Arneh Babakhani; Todd T Talley; Palmer Taylor; J A McCammon
Journal:  Comput Biol Chem       Date:  2009-01-08       Impact factor: 2.877

Review 9.  Emerging methods for ensemble-based virtual screening.

Authors:  Rommie E Amaro; Wilfred W Li
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

10.  Binding modes of peptidomimetics designed to inhibit STAT3.

Authors:  Ankur Dhanik; John S McMurray; Lydia E Kavraki
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.